Willy Simon - Rasna Therapeutics Ex Chairman

All Insiders . USA . 
Stock . Rasna Therapeutics . Stakeholders . Insider . Willy Simon
RASP Stock  USD 0  0.00  0.00%   

Insider

Willy Simon is Ex Chairman of Rasna Therapeutics
Age 72
Phone646 396 4087
Webhttps://www.rasna.com

Rasna Therapeutics Management Efficiency

The company has return on total asset (ROA) of (3.6957) % which means that it has lost $3.6957 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.9359) %, meaning that it created substantial loss on money invested by shareholders. Rasna Therapeutics' management efficiency ratios could be used to measure how well Rasna Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
Rasna Therapeutics currently holds 91.97 K in liabilities with Debt to Equity (D/E) ratio of 0.2, which may suggest the company is not taking enough advantage from borrowing. Rasna Therapeutics has a current ratio of 0.04, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Rasna Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Rasna Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Rasna Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Rasna to invest in growth at high rates of return. When we think about Rasna Therapeutics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Prof MDVentyx Biosciences
N/A
Rami ElghandourArcellx
45
Eddie SullivanSAB Biotherapeutics
58
Amy JudgePreinImmunocore Holdings
N/A
Annelise VuidepotImmunocore Holdings
N/A
Karen AldereteVaxcyte
N/A
Theis MDGH Research PLC
48
Bahija JallalImmunocore Holdings
63
Grant MBAVaxcyte
56
Jeff FenstererAccustem Sciences
44
Florian MGH Research PLC
55
Adi ZuloffShaniScisparc
55
Brian MBAImmunocore Holdings
57
Neeraj TeotiaArcellx
49
Jeff FairmanVaxcyte
60
Ranga MDIndia Globalization Capital
60
Narinderjeet MSArcellx
52
Martin MDVentyx Biosciences
49
DCPSA FFPMBionomics Ltd ADR
N/A
Debra NielsenImmunocore Holdings
N/A
Oz CPAScisparc
37
Rasna Therapeutics, Inc., a leukemia-focused biotechnology company, engages in developing therapeutics for the treatment of acute myeloid leukemia and other forms of leukemia and lymphoma. Rasna Therapeutics, Inc. was founded in 2013 and is headquartered in New York, New York. Rasna Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange. Rasna Therapeutics [RASP] is a Pink Sheet which is traded between brokers as part of OTC trading.

Management Performance

Return On Equity-2.94
Return On Asset-3.7

Rasna Therapeutics Leadership Team

Elected by the shareholders, the Rasna Therapeutics' board of directors comprises two types of representatives: Rasna Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rasna. The board's role is to monitor Rasna Therapeutics' management team and ensure that shareholders' interests are well served. Rasna Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rasna Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Keeren Shah, F Director
Willy Simon, Ex Chairman

Rasna Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Rasna Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-2.94
Return On Asset-3.7
Current Valuation1.22 M
Shares Outstanding771.81 M
Shares Owned By Insiders85.10 %
Price To Book0.31 X
EBITDA254.41 K
Net Income(686.59 K)
Cash And Equivalents10.52 K
Total Debt91.97 K

Additional Tools for Rasna Pink Sheet Analysis

When running Rasna Therapeutics' price analysis, check to measure Rasna Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rasna Therapeutics is operating at the current time. Most of Rasna Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rasna Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rasna Therapeutics' price. Additionally, you may evaluate how the addition of Rasna Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY